A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2015
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Fotemustine
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms NIBIT-M2
- 29 May 2015 According to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology 17 patients have been enrolled till date.
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
- 10 Mar 2014 New trial record